Latest Docetaxel Stories
AFFINITY Trial to Continue as Planned Following Completion of Interim Futility Analysis BOTHELL, Wash. and VANCOUVER, British Columbia, Jan.
- Patent Covers Taxane Prodrug Nanoparticle Delivery Technology - EWING, N.J., Dec. 18, 2014 /PRNewswire/ -- Celator Pharmaceuticals, Inc.
CYRAMZA is the first treatment approved in the U.S. for use in combination with docetaxel in second-line metastatic non-small cell lung cancer INDIANAPOLIS, Dec.
The FDA has approved the drug Cyramza, to be used in combination with docetexal for the treatment of non-small-cell lung cancer (NSCLC).
Final data after 49-month follow-up analysis in chemotherapy-naïve men with metastatic castration-resistant prostate cancer presented at European Society for Medical Oncology (ESMO) 2014 Congress
Approval based on improved overall survival, delayed time to radiographic progression and an overall positive benefit-risk profile TOKYO and SAN FRANCISCO, Sept.
ENSPIRIT Trial to Continue as Planned Following Completion of the First of Two Interim Futility Analyses BOTHELL, Wash. and VANCOUVER, British Columbia, Aug.
The Majority of Surveyed Non-Prescribers Anticipate Prescribing Xofigo Within the Next Six Months, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.
On June 20, the FDA issued a warning that Docetaxel may cause intoxication.
-- REVEL Data Published in The Lancet, Presented at Annual ASCO Meeting -- CHICAGO, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from REVEL,
- totally perplexed and mixed up.